SLC5A2 and hydrops fetalis: A recent meta-analysis of several clinical trials, which involved approximately 17,000 individuals, has concluded that SGLT2 inhibitors markedly reduce heart failure hospitalizations (HFH), adverse renal effects, and HF mortality consistently in diabetic and nondiabetic patients [22].